Oncotarget: Company News & Trending with Impact
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | @Blagosklonny
TRENDING WITH IMPACT: Altmetric Scores & Company News
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. Learn about the six components of the Oncotarget Scientific Integrity process: Presence of Ethics Statements, Adherence to Scientific Publishing Standards, Rigorous and Insightful Peer Review, Elimination of Plagiarism, Image Forensics, and Post-Publication Investigations.
The Trending with Impact series highlights Oncotarget publications that are attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels. Oncotarget is proud to offer Altmetric scores on papers for readers online. With one click via the Altmetric donut badges to the left of the paper title, you may learn about the recorded original shares and mentions the paper appears in. Oncotarget believes that this level of information available to readers increases journal dependability and trust. A list of publications with an Altmetric score higher than 100 can be found at Oncotarget.com/news/altmetric.
In addition to trending papers, readers may also find Oncotarget company news published on mikhailblagosklonnyoncotarget.com, including the announcement of Special Collections. Look for future science news and articles about the latest trending publications here, at Oncotarget.org, and Oncotarget.com. To hear directly from the distinguished network of authors who continue to publish their research with Oncotarget and learn about our community-based news and events, visit Oncotarget.net.
CONTACT INFORMATION:
For additional information about the Oncotarget Journal, follow us on X @Oncotarget or visit the website.
For media inquiries, please contact media@impactjournals.com.
Mikhailblagosklonny.com | Oncotarget.org | Oncotarget.net | Oncotarget.com